BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry

Biotech 1 min
July 30, 2020

COVID-19 presents an unprecedented challenge to the global life sciences industry.  Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located.  This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

Today we release the latest in our series, focusing on Market Access, please click on the link below to view this tracker:

Other trackers available in this series:

  • COVID-19: Legislation Tracker for Medical Devices, read here
  • COVID-19: Legislation Tracker for Clinical Trials, read here
  • COVID-19: Legislation Tracker for Public Procurement, read here
  • COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here

Related articles

“Effective enforcement of EU competition rules in the pharmaceutical law remains a matter of high priority…”
So notes the Commission's report on competition enforcement in the pharmaceutical sector (2009-2017)...
Supreme Court defines plausibility in the context of sufficiency
A majority postulates a new "outward presentation test" to deal with the infringement of second medical...